This compound is primarily used in the field of targeted protein degradation. It functions as a PROTAC (Proteolysis Targeting Chimera) specifically designed to target PTK6 (Protein Tyrosine Kinase 6). By binding to PTK6, it recruits an E3 ubiquitin ligase, leading to the ubiquitination and subsequent degradation of PTK6 via the proteasome pathway. This mechanism is particularly valuable in cancer research, as PTK6 is often overexpressed in various cancers and contributes to tumor growth and progression. The application of this compound allows researchers to study the effects of PTK6 inhibition and degradation, potentially leading to the development of novel cancer therapies. Additionally, it serves as a tool to explore the role of PTK6 in cellular signaling pathways and its impact on disease mechanisms.